S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 40 of 55

Issue Date	Title / Author(s) / Citation	File
2006-06	Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer Lee, Kyung-Hun; Han, Sae-Won; Hwang, Pil Gyu; Oh, Do-Youn; Kim, Dong-Wan; Chung, Doo Hyun; Im, Seock-Ah; Kim, Tae-You; Heo, Dae Seog; Bang, Yung-Jue Japanese Journal of Clinical Oncology, Vol.36 No.6, pp.344-350	DOI
2008-03	High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer Kim, D-W; Min, H. S.; Lee, K-H; Kim, Y. J.; Oh, D-Y; Jeon, Y. K.; Lee, S. -H.; Im, S. -A.; Chung, D. H.; Kim, Y. T.; Kim, T. -Y.; Bang, Y. -J.; Sung, S. W.; Kim, J. H.; Heo, D. S. British Journal of Cancer, Vol.98 No.6, pp.1118-1124	DOI
2008-06	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer Lee, Kyung-Hun; Min, Hye Sook; Han, Sae-Won; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Chung, Doo Hyun; Kim, Young Tae; Kim, Tae-You; Heo, Dae Seog; Bang, Yung-Jue; Sung, Sook Whan; Kim, Joo Hyun Lung Cancer, Vol.60 No.3, pp.401-407	DOI
2008-07	Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment Han, Sae-Won; Kim, Hwang-Phill; Jeon, Yoon Kyung; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Chung, Doo Hyun; Heo, Dae Seog; Bang, Yung-Jue; Kim, Tae-You Lung Cancer, Vol.61 No.1, pp.30-34	DOI
2009-07	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI Yi, Hyeon Gyu; Kim, Hye Jin; Kim, Yu Jung; Han, Sae-Won; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Kim, Tae-You; Kim, Chul Soo; Heo, Dae Seog; Bang, Yung-Jue Lung Cancer, Vol.65 No.1, pp.80-84	DOI
2009-09	Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells Yoon, Young-Kwang; Kim, Hwang-Phill; Han, Sae-Won; Hur, Hyung-Seok; Oh, Do Youn; Im, Seock-Ah; Bang, Yung-Jue; Kim, Tae-You Molecular Cancer Therapeutics, Vol.8 No.9, pp.2526-2536	DOI
2010-04	KRAS Mutant Lung Cancer Cells Are Differentially Responsive to MEK Inhibitor Due to AKT or STAT3 Activation: Implication for Combinatorial Approach Yoon, Young-Kwang; Kim, Hwang-Phill; Han, Sae-Won; Oh, Do Youn; Im, Seock-Ah; Bang, Yung-Jue; Kim, Tae-You Molecular Carcinogenesis, Vol.49 No.4, pp.353-362	DOI
2010-10	Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer Kwak, Eunice L.; Bang, Yung-Jue; Camidge, D. Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Jaenne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, S. Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John New England Journal of Medicine, Vol.363 No.18, pp.1693-1703	DOI
2011-02	Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes Ku, Ja-Lok; Kim, Kyung-Hee; Choi, Jin-Sung; Jeon, You-Kyung; Kim, Sung-Hee; Shin, Young-Kyoung; Kim, Tae-You; Bang, Yung-Jue; Kim, Woo Ho; Park, Jae-Gahb Cellular Oncology, Vol.34 No.1, pp.45-54	DOI
2011-03	Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer Nam, Hyun-Jin; Kim, Hwang-Phill; Yoon, Young-Kwang; Hur, Hyung-Seok; Song, Sang-Hyun; Kim, Maeng-Sup; Lee, Gwan-Sun; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Oh, Do-Youn; Bang, Yung-Jue Cancer Letters, Vol.302 No.2, pp.155-165	DOI
2011-05	Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma Suggestion for an Effective Screening Strategy for These Tumors Koh, Youngil; Kim, Dong-Wan; Kim, Tae Min; Lee, Se-Hoon; Jeon, Yoon Kyung; Chung, Doo Hyun; Kim, Young-Whan; Heo, Dae Seog; Kim, Woo-Ho; Bang, Yung-Jue Journal of Thoracic Oncology, Vol.6 No.5, pp.905-912	DOI
2011-05	Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification Ou, Sai-Hong Ignatius; Kwak, Eunice L.; Siwak-Tapp, Christina; Dy, Joni; Bergethon, Kristin; Clark, Jeffrey W.; Camidge, D. Ross; Solomon, Benjamin J.; Maki, Robert G.; Bang, Yung-Jue; Kim, Dong-Wan; Christensen, James; Tan, Weiwei; Wilner, Keith D.; Salgia, Ravi; Iafrate, A. John Journal of Thoracic Oncology, Vol.6 No.5, pp.942-946	DOI
2011-10	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Shaw, Alice T.; Yeap, Beow Y.; Solomon, Benjamin J.; Riely, Gregory J.; Gainor, Justin; Engelman, Jeffrey A.; Shapiro, Geoffrey I.; Costa, Daniel B.; Ou, Sai-Hong I.; Butaney, Mohit; Salgia, Ravi; Maki, Robert G.; Varella-Garcia, Marileila; Doebele, Robert C.; Bang, Yung-Jue; Kulig, Kimary; Selaru, Paulina; Tang, Yiyun; Wilner, Keith D.; Kwak, Eunice L.; Clark, Jeffrey W.; Iafrate, A. John; Camidge, D. Ross The Lancet Oncology, Vol.12 No.11, pp.1004-1012	DOI
2012-06	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma Paik, Jin Ho; Choi, Chang-Min; Kim, Hyojin; Jang, Se Jin; Choe, Gheeyoung; Kim, Dong Kwan; Kim, Hwa Jung; Yoon, Hoil; Lee, Choon-Taek; Jheon, Sanghoon; Choe, Ji-Young; Chung, Jin-Haeng Lung Cancer, Vol.76 No.3, pp.403-409	DOI
2012-08	Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients Park, Heae Surng; Lee, June Koo; Kim, Dong-Wan; Kulig, Kimary; Kim, Tae Min; Lee, Se-Hoon; Jeon, Yoon-Kyung; Chung, Doo Hyun; Heo, Dae Seog Lung Cancer, Vol.77 No.2, pp.288-292	DOI
2012-08	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation Lee, June Koo; Kim, Tae Min; Koh, Youngil; Lee, Se-Hoon; Kim, Dong-Wan; Jeon, Yoon-Kyung; Chung, Doo Hyun; Yang, Seok-Chul; Kim, Young Tae; Kim, Young-Whan; Heo, Dae Seog; Bang, Yung-Jue Lung Cancer, Vol.77 No.2, pp.460-463	DOI
2012-09	Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis Bae, Hyun-Mi; Lee, Se-Hoon; Kim, Tae Min; Kim, Dong-Wan; Yang, Seok-Chul; Wu, Hong Gyun; Kim, Young Whan; Heo, Dae Seog Lung Cancer, Vol.77 No.3, pp.572-577	DOI
2013-03	Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT Choi, Hongyoon; Paeng, Jin Chul; Kim, Dong-Wan; Lee, June Koo; Park, Chang Min; Kang, Keon Wook; Chung, June-Key; Lee, Dong Soo Lung Cancer, Vol.79 No.3, pp.242-247	DOI
2013-06	Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crino, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Jaenne, Pasi A. New England Journal of Medicine, Vol.368 No.25, pp.2385-2394	DOI
2013-08	Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study Lee, J. K.; Shin, J. -Y.; Kim, S.; Lee, S.; Park, C.; Kim, J. -Y.; Koh, Y.; Keam, B.; Min, H. S.; Kim, T. M.; Jeon, Y. -K.; Kim, D. -W.; Chung, D. H.; Heo, D. S.; Lee, S. -H.; Kim, J. -I. Annals of Oncology, Vol.24 No.8, pp.2080-2087	DOI
2014-02	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC Ou, Sai-Hong I.; Jaenne, P. A.; Bartlett, C. H.; Tang, Y.; Kim, D. -W.; Otterson, G. A.; Crino, L.; Selaru, P.; Cohen, D. P.; Clark, J. W.; Riely, G. J. Annals of Oncology, Vol.25 No.2, pp.415-422	DOI
2014-03	Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer Shaw, Alice T.; Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S. W.; Felip, Enriqueta; Chow, Laura Q. M.; Camidge, D. Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J.; Solomon, Benjamin J.; Wolf, Juergen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Lau, Yvonne Y.; Goldwasser, Meredith; Boral, Anthony L.; Engelman, Jeffrey A. New England Journal of Medicine, Vol.370 No.13, pp.1189-1197	DOI
2014-04	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non-Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor A Meta-analysis Lee, June-Koo; Hahn, Seokyung; Kim, Dong-Wan; Suh, Koung Jin; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Heo, Dae Seog JAMA - Journal of the American Medical Association, Vol.311 No.14, pp.1430-1437	DOI
2014-09	AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William Cancer Discovery, Vol.4 No.9, pp.1046-1061	DOI
2014-10	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Keam, Bhumsuk; Kim, Dong-Wan; Park, Jin Hyun; Lee, Jeong-Ok; Kim, Tae Min; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog Cancer Research and Treatment, Vol.46 No.4, pp.323-330	view file DOI
2014-11	Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-Small-Cell Lung Cancer Blackhall, Fiona; Kim, Dong-Wan; Besse, Benjamin; Nokihara, Hiroshi; Han, Ji-Youn; Wilner, Keith D.; Reisman, Arlene; Iyer, Shrividya; Hirsh, Vera; Shaw, Alice T. Journal of Thoracic Oncology, Vol.9 No.11, pp.1625-1633	DOI
2014-12	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial Jaenne, Pasi A.; Ou, Sai-Hong I.; Kim, Dong-Wan; Oxnard, Geoffrey R.; Martins, Renato; Kris, Mark G.; Dunphy, Frank; Nishio, Makoto; O'Connell, Joseph; Paweletz, Cloud; Taylor, Ian; Zhang, Hui; Goldberg, Zelanna; Mok, Tony The Lancet Oncology, Vol.15 No.13, pp.1433-1441	DOI
2014-12	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score Lee, Dae-Won; Shin, Dong-Yeop; Kim, Jin Wook; Keam, Bhumsuk; Kim, Tae Min; Kim, Hak Jae; Kim, Dong-Wan; Wu, Hong-Gyun; Paek, Sun Ha; Kim, Young Whan; Heo, Dae Seog; Kim, Dong Gyu; Lee, Se-Hoon Lung Cancer, Vol.86 No.3, pp.363-368	DOI
2015-01	Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer Lee, H. J.; Seo, A. N.; Kim, E. J.; Jang, M. H.; Kim, Y. J.; Kim, J. H.; Kim, S. -W.; Ryu, H. S.; Park, I. A.; Im, S. -A.; Gong, G.; Jung, K. H.; Kim, H. J.; Park, S. Y. British Journal of Cancer, Vol.112 No.1, pp.103-111	DOI
2015-02	Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor Won, J. K.; Keam, B.; Koh, J.; Cho, H. J.; Jeon, Y. K.; Kim, T. M.; Lee, S. H.; Lee, D. S.; Kim, D. W.; Chung, D. H. Annals of Oncology, Vol.26 No.2, pp.348-354	DOI
2015-04	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer Jaenne, Pasi A.; Yang, James Chih-Hsin; Kim, Dong-Wan; Planchard, David; Ohe, Yuichiro; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Su, Wu-Chou; Horn, Leora; Haggstrom, Daniel; Felip, Enriqueta; Kim, Joo-Hang; Frewer, Paul; Cantarini, Mireille; Brown, Kathryn H.; Dickinson, Paul A.; Ghiorghiu, Serban; Ranson, Malcolm New England Journal of Medicine, Vol.372 No.18, pp.1689-1699	DOI
2015-04	The impact of molecularly targeted treatment on direct medical costs in patients with advanced non-small cell lung cancer Lee, June-Koo; Kim, Dong-Wan; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Young-Joo; Heo, Dae Seog Cancer Research and Treatment, Vol.47 No.2, pp.182-188	view file DOI
2015-05	Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer Song, Ahnah; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Keam, Bhumsuk; Lee, Se-Hoon; Heo, Dae Seog Clinical Cancer Research, Vol.21 No.10, pp.2379-2387	DOI
2015-10	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations Park, Sehhoon; Keam, Bhumsuk; Kim, Se Hyun; Kim, Ki Hwan; Kim, Yu Jung; Kim, Jin-Soo; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Lee, Jong Seok; Heo, Dae Seog Cancer Research and Treatment, Vol.47 No.4, pp.630-637	view file DOI
2015-12	Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor Kim, Tae Min; Song, Ahnah; Kim, Dong-Wan; Kim, Soyeon; Ahn, Yong-Oon; Keam, Bhumsuk; Jeon, Yoon Kyung; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog Journal of Thoracic Oncology, Vol.10 No.12, pp.1736-1744	DOI
2015-12	MET amplification, protein expression, and mutations in pulmonary adenocarcinoma Park, Seongyeol; Koh, Jaemoon; Kim, Dong-Wan; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Chung, Doo Hyun; Heo, Dae Seog Lung Cancer, Vol.90 No.3, pp.381-387	DOI
2016-02	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) Lee, Ji Yun; Xu Qing; Wei Xiumin; Bai Yali; Chi, Sangah; Bak, So Hyeon; Lee, Ho Yun; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Cho, Eun Kyung; Kim, Dong-Wan; Kim, Hye Ryun; Min, Young Joo; Jung, Sin-Ho; Park, Keunchil; Mao Mao; Ahn, Myung-Ju Oncotarget, Vol.7 No.6, pp.6984-6993	view file DOI
2016-03	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D. Annals of Oncology, Vol.27 No.3, pp.417-423	DOI
2016-03	Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors Sim, Sung Hoon; Beom, Seung-Hoon; Ahn, Yong-Oon; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Heo, Dae Seog Thoracic Cancer, Vol.7 No.2, pp.161-166	view file DOI
2016-04	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies Planchard, David; Brown, Kathryn H.; Kim, Dong-Wan; Kim, Sang-We; Ohe, Yuichiro; Felip, Enriqueta; Leese, Philip; Cantarini, Mireille; Vishwanathan, Karthick; Jaenne, Pasi A.; Ranson, Malcolm; Dickinson, Paul A. Cancer Chemotherapy and Pharmacology, Vol.77 No.4, pp.767-776	DOI

1 2